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Should We Operate on Asymptomatic Patients
With Severe Mitral Regurgitation?*
Paul A. Grayburn, MD, FACC
Dallas, TexasThe timing of surgery for chronic severe mitral
regurgitation (MR) in asymptomatic patients with
normal left ventricular (LV) function remains con-
troversial. On the one hand, the natural history of
chronic severe MR indicates a high likelihood of
eventual progression to symptoms or LV dysfunc-
tion (1–3). In addition, hemodynamic compensa-
tion may allow LV size and ejection fraction to
remain normal, even when myocardial dysfunction
is already present (4,5). These factors, along with
the physician’s ability to perform mitral valve repair
with an operative mortality 1%, have led some to
consider prophylactic mitral valve surgery to prevent
the inevitable development of LV dysfunction be-
fore it becomes irreversible. On the other hand, it is
See page 133
impossible to make an asymptomatic patient feel
better after heart surgery, and there is evidence that
a strategy of “watchful waiting,” in which surgery is
delayed until the first onset of either symptoms or
LV dysfunction, is effective (6). The American
College of Cardiology/American Heart Association
Guidelines state that surgery for asymptomatic
patients with chronic severe MR and normal LV
size and function may be considered, provided that
there is a 90% likelihood of successful valve repair
(7). In this issue of JACC: Cardiovascular Imaging, a
new study by Grigioni et al. (8) casts further light
*Editorials published in the JACC: Cardiovascular Imaging reflect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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from whom he receives grant support.on this topic and raises some interesting and pro-
vocative questions.
Grigioni et al. (8) present a prospective, multi-
center observational study of 394 patients, all of
whom had flail leaflet by echocardiography. This
population is a rather homogenous one because flail
leaflet is a reliable marker of pure organic MR, is
almost always accompanied by severe MR, and has
been shown to be associated with an adverse prog-
nosis, including sudden cardiac death. Most of the
patients had degenerative, presumably myxomatous
mitral valve disease, although in 9% the flail leaflet
was caused by endocarditis. In most patients, only
the posterior leaflet was flail (79%); the anterior
leaflet alone was flail in 8% and both leaflets in 12%.
Only 9% of patients had significant coronary artery
disease. The decision to operate was left to the
discretion of the attending physician. Surgery was
performed in 315 (80%) with an excellent 30-day
operative mortality (0.7%). Only 47 (15%) of these
patients underwent prophylactic surgery; the major-
ity had surgery for symptoms (68%), LV dilation
(6%), endocarditis (5%), or other reasons not spec-
ified. Mitral valve repair was performed in 80% and
replacement in 20%. By multivariate analysis, sur-
gery reduced the risk of death and heart failure
independently of age, functional class, and LV
ejection fraction. Not surprisingly, this benefit was
driven mainly by mitral valve repair. The 5-year
survival was 92% with valve repair, 86% during
nonsurgical management, and 80% after valve re-
placement.
In the subgroup of 102 patients who were asymp-
tomatic with normal LV size and function, survival
with nonsurgical management was excellent (97%
5-year survival), although atrial fibrillation (4%/
year) or heart failure (5.7%/year) was common.
Eventually, surgery was performed in 70 (69%) of
these patients with no perioperative deaths. Mitral
v
i
s
w
p
R
w
o
g
m
f
v
r
P
y
v
1
G
e
b
t
L
u
c
o
m
a
m
t
w
r
b
l
q
s
s
p
i
i
a
t
u
h
d
m
e
e
(
A
m
r
a
s
p
w
G
b
r
c
h
T
p
r
a
t
o
d
u
S
4
g
v
i
h
t
c
d
s
d
s
fl
m
c
f
r
c
t
t
s
w
p
w
f
a
o
R
B
c
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 , N O . 2 , 2 0 0 8
M A R C H 2 0 0 8 : 1 4 2 – 4
Grayburn
Editorial Comment
143alve repair was performed in 82% and replacement
n 18%. The data from this important subgroup are
imilar to those published by Rosenhek et al. (6),
ho showed a 96% 4-year survival in asymptomatic
atients with normal LV size and function. In the
osenhek et al. (6) study, a purposeful strategy of
atchful waiting was used, such that surgery was
nly performed for onset of symptoms, echocardio-
raphic LV dysfunction, atrial fibrillation, or pul-
onary hypertension. Surgery was eventually per-
ormed in 35 patients, 83% of whom underwent
alve repair, and 17% of whom underwent valve
eplacement. There were no perioperative deaths.
atients in the Rosenhek et al. (6) study were
ounger (55 vs. 64 years), more likely female (49%
s 33%), and less likely to have flail leaflet (44% vs
00%) compared with those in the present study by
rigioni et al. (8). These patient differences may
xplain the greater rate of surgery in the latter study,
ut overall, both studies show an excellent long-
erm survival in asymptomatic patients with normal
V size and function, even when surgery is delayed
ntil clinical indications appear.
If in fact, we propose to operate early in the
ourse of severe MR, before the onset of symptoms
r LV dysfunction, several prerequisites must be
et. First, it is imperative to be sure that MR is
ctually severe. Patients occasionally are referred for
itral valve surgery based on an echocardiogram
hat was incorrectly interpreted as “severe” MR,
hen no murmur is present, the mitral valve appa-
atus is structurally normal, and review of the data
y an expert observer reveals only mild MR. Guide-
ines for assessing MR severity, including important
uantitative parameters, have been published and
hould be applied (9). In the Grigioni et al. (8)
tudy, this was not an issue because all of the
atients had flail leaflet, and the authors are experts
n echocardiographic assessment of MR. Second, it
s necessary to be sure that the patient is truly
symptomatic. Exercise testing to establish func-
ional class and/or stress echocardiography to eval-
ate LV end-systolic response to exercise may be
elpful in this regard (10). Third, it is important to
etermine beforehand the likelihood of successful
itral valve repair, which should be performed in
xperienced centers by surgeons with established
xpertise in the various types of mitral valve repair
7). The American College of Cardiology/
merican Heart Association Guidelines state that
itral valve repair in asymptomatic patients is Teasonable so long as the valve can be repaired with
90% success rate (7). There are 2 aspects to that
tatement. One is the accurate predictive value of
reoperative echocardiography in determining
hether the valve can be repaired or not. In the
rigioni et al. (8) and Rosenhek et al. (6) studies,
oth done at expert centers, the rate of mitral valve
epair was 80%, which is much lower than expected,
onsidering that in both of these studies, all patients
ad either mitral valve prolapse or flail leaflets.
hese are all type II valves according to the Car-
entier classification and should have a 90% success
ate for mitral valve repair (11). In the Grigioni et
l. (8) study, it is not clear how often the valves were
hought to be repairable by preoperative echocardi-
graphy, and the surgical anatomy was found to be
ifferent, or how often repair was attempted but
nsuccessful. Data from the Society of Thoracic
urgery Database show that, in 2006, there were
,901 isolated (without concomitant bypass sur-
ery) mitral valve repairs and 4,339 isolated mitral
alve replacements, nearly a 1:1 ratio (12). This
ndicates that the best operation, mitral valve repair,
as not penetrated well enough into general prac-
ice. Perhaps it is time to consider establishing
enters of excellence for valve surgery, as has been
one successfully with level III trauma centers.
A flail mitral valve leaflet is associated with a
ignificant risk of developing heart failure, LV
ysfunction, atrial fibrillation, pulmonary hyperten-
ion, and death (8,13–15). There is no question that
ail leaflet is a surgical disease; there is no effective
edical therapy for this condition. Although per-
utaneous techniques of mitral valve repair are
orthcoming (16,17), surgical mitral valve repair
emains the standard of care for flail leaflet and is
learly superior to valve replacement. However, the
iming of valve repair is still a matter of debate. If
he patient is truly asymptomatic with normal LV
ize and function, it is reasonable to use a strategy of
atchful waiting. It is also reasonable to perform
rophylactic surgery, but only if repair is feasible
ith a 90% likelihood in an expert center. Un-
ortunately, we might not be as good as we think we
re in assessing feasibility of repair and carrying it
ut successfully.
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